# K121987

510(k) SUMMARY

1. Date:

July 23, 2012

Submitter:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641

AUG 1 2012

3.Contact person:

Joe Shia   
LSI International Inc.   
504 East Diamond Ave., Suite F Gaithersburg, MD 20878   
Telephone: 240-505-7880   
Fax: 301-916-6213   
Email:shiajl@yahoo.com

4Device Name:

Wondfo Amphetamine Urine Test Wondfo Secobarbital Urine Test Wondfo Oxazepam Urine Test

# Classification:

5Predicate Devices:

Product Code CFR # DKZ 21CFR 862.3100 DIS 21CFR 862.3150 JXM 21CFR 862.3170

K020771

Acon Laboratories, Inc. One Step Drug Screen Test

6Intended Use

Wondfo Amphetamine, Secobarbital, and Oxazepam Urine Tests are intended for the qualitative determination of d-Amphetamine , Secobarbital, and Oxazepam at a specific cut-off concentration in human urine samples. They are intended for healthcare professional use and over the counter use.

# Device Description

Immunochromatograph assays for Amphetamine, Secobarbital, and Oxazepam Urine Tests use a lateral flow, one step system for the qualitative detection of d-Amphetamine , Secobarbital, and Oxazepam (target analyte) in human urine. Each assay uses a monoclonal antibody-dye conjugate against drugs with gold chloride and fixed drug-protein conjugates and anti-mouse IgG polyclonal antibody in membranes.

# 8. Substantial Equivalence Information

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indication(s) foruse</td><td rowspan=1 colspan=1>For the qualitative determination ofAmphetamine, Barbiturates,Benzodiazepines individual in humanurine.</td><td rowspan=1 colspan=1>Same (but the numberof drugs detecteddifferent)</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assays basedon the principle of antigen antibodyimmunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type Of Test</td><td rowspan=1 colspan=1>Immunoassay principles that rely onantigen-antibody interactions toindicate positive or negative result</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>Amphetamine: 1000ng/mlSecobarbital : 300 ng/mlOxazepam: 300ng/ml</td><td rowspan=1 colspan=1>Same (but thenumber of drugsdetected different)</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup, dip card</td><td rowspan=1 colspan=1>Strip, Device</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>OTC Use &amp; Prescription Use</td><td rowspan=1 colspan=1>Prescription Use</td></tr></table>

9 Standard/Guidance Document Reference

Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982. . Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New York, 1988 • Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring - Verlag, 1977. • Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992. • Hawwks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986 • Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University Press, 1983. • McBay, A. J. Clin. Chem. 33,33B-40B, 1987

10. Test Principle

It is a rapid test for the qualitative detection of d-Amphetamine, Secobarbital, and Oxazepam in urine samples. It is a lateral flow chromatographic immunoassay. When the absorbent end is immersed into a urine sample, the urine is absorbed into the device by capillary action and mixes with the antibody-dye conjugate, flowing across the pre-coated membrane. At analyte concentration below the target cut off, antibody-dye conjugates bind to the drug-protein conjugate immobilized in the Test Region (T) of the device.

This produces a colored test line that indicates a negative result. When analyte concentration is above the cutoff, analyte molecules bind to the antibody-dye conjugate, preventing the antibody-dye conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. No colored band shows in the test region, indicating a potentially positive result.

11. Performance Characteristics

1Analytical Performance

a. Precision

Precision studies were carried out for samples with concentrations of - $1 0 0 \%$ cut off, $- 7 5 \%$ cut off, $- 5 0 \% { \tt c u t }$ off, $- 2 5 \%$ cut off, $+ 2 5 \%$ ocut off, $+ 5 0 \%$ cut off , $+ 7 5 \%$ bcut off and $+ 1 0 0 \%$ ocut off. For each concentration, tests were performed two runs per day for 25 days. The results obtained are summarized in the following table.

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>-100%cutoff</td><td rowspan=1 colspan=1>-75%cutoff</td><td rowspan=1 colspan=1>-50%cutoff</td><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>cutoff</td><td rowspan=1 colspan=1>+25%cutoff</td><td rowspan=1 colspan=1>+50%cutoff</td><td rowspan=1 colspan=1>+75%cutoff</td><td rowspan=1 colspan=1>+100%cutoff</td></tr><tr><td rowspan=1 colspan=1>AMP</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

b.Linearity Not applicable c. Stability

It is stable at $4 { \cdot } 3 0 ^ { \circ } \mathrm { C }$ for 23 months.

d.Cut-off e. Interference

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off (ng/ml)</td></tr><tr><td rowspan=1 colspan=1>Amphetamine(AMP)</td><td rowspan=1 colspan=1>D-Amphetamine.</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>300</td></tr></table>

Compounds that show no interference at a concentration of $1 0 0 ~ \mu \mathrm { g / m L }$ are summarized in the following tables.

# AMP

4-Acetamidophenol (-) Y Ephedrine Penicillin-G Acetophenetidin Erythromycin Pentazocaine N-Acetylprocainamide EPY $\beta .$ Estradiol Pentobarbital Acetylsalicylic acid Estrone-3-sulfate Perphenazine Aminopyrine Ethyl-p-aminobenzoate Phencyclidine Amitryptyline Fenfluramine Phenelzine Amobarbital Fenoprofen Phendimetrazine Amoxicillin Furosemide Phenobarbital Ampicillin Gentisic acid Phetoin Ascorbic acid Hemoglobin L-Phenylephrine Apomorphine Hydralazine $\beta$ Phenylethlamine Aspartame Hydrochlorothiazide Phenylpropanolamine Atropine Hydrocodone Prednisolone Benzilic acid Hydrocortisone Prednisone Benzoic acid O-Hydroxyhippuric acid Procaine Benzoylecgonine $3$ Hydroxytyramine Promazine Bilirubin Ibuprofen Promethazine Brompheniramine Imipramine D,L-Propanolol Caffeine (-) Isoproterenol Propiomazine Cannabidiol Isoxsuprine D-Propoxyphene Cannabinol Ketamine Quinidine Chloralhydrate Ketoprofen Quinine Chloramphenicol Labetalol Ranitidine Chlordiazepoxide Levorphanol Salicylic acid Chlorothiazide Loperamide Secobarbital $( \pm )$ Chlorpheniramine Maprotiline Serotonin Chlorpromazine Meperidine Sulfamethazine Chlorquine Meprobamate Sulindac Cholesterol Methadone Temazepam Clomipramine Methylphenidate Tetracycline Clonidine Morphine-3-Dglucuronide Tetrahydrocortisone Cocaine hydrochloride Nalidixic acid Tetrahydrozoline Codeine Naloxone $\Delta 9$ THC-COOH Cortisone Naltrexone Thebaine (-) Cotinine Naproxen Thiamine Creatinine Niacinamide Thioridazine Deoxycorticosterone Nifedipine D,L-Thyroxine Dextromethorphan Norcodein Tolbutamine Diazepam Norethindrone Triamterene

Diclofenac D-Norpropoxyphene Trifluoperazine Diflunisal Noscapine Trimethoprim Digoxin D,L-Octopamine Trimipramine Diphenhydramine Oxalic acid Tryptamine Doxylamine Oxazepam D, L-Tyrosine Ecgonine hydrochloride Oxolinic acid Uric acid Ecgonine methylester Oxycodone Verapamil (IR,2S)-(-)-Ephedrine Oxymetazoline Zomepirac L-Ephedrine Papaverine

Secobarbital Acetaminophen L-Ephedrine Acetophenetidin Erythromycin N-Acetylprocainamide EPY $\beta$ Estradiol Acetylsalicylic acid Estrone-3-sulfate Aminopyrine Ethyl $\mathfrak { p }$ -aminobenzoate Amitryptyline Fenfluramine Amoxicillin Fenoprofen Ampicillin Furosemide Ascorbic acid Gentisic acid Apomorphine Hemoglobin Aspartame Hydralazine Benzilic acid Hydrochlorothiazide Benzoic acid Hydrocodone Benzoylecgonine Hydrocortisone Bilirubin O-Hydroxyhippuric acid Brompheniramine 3-Hydroxytyramine Caffeine Ibuprofen Cannabidiol Imipramine Cannabinol (-) Isoproterenol Chloralhydrate Isoxsuprine Chloramphenicol Ketamine Chlordiazepoxide Ketoprofen Chlorothiazide Labetalol E $( \pm )$ Chlorpheniramine Levorphanol Chlorpromazine Loperamide Chlorquine Maprotiline Cholesterol Meperidine Clomipramine Meprobamate Clonidine Methadone Cocaine hydrochloride Methylphenidate Codeine Morphine-3 $\cdot \ B \cdot$ -D glucuronide Cortisone Nalidixic acid (-) Cotinine Naloxone Creatinine Naltrexone Deoxycorticosterone Naproxen

Oxycodone   
Oxymetazoline   
Papaverine   
Penicillin-G   
Pentazocaine   
Perphenazine   
Phencyclidine   
Phenelzine   
Phendimetrazine   
Phetoin   
L-Phenylephrine   
EPY $\beta$ Phenylethlamine   
Phenylpropanolamine   
Prednisolone   
Prednisone   
Procaine   
Promazine   
Promethazine   
D,L-Propanolol   
Propiomazine   
D-Propoxyphene   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Serotonin   
Sulfamethazine   
Sulindac   
Temazepam   
Tetracycline   
Tetrahydrocortisone   
· Tetrahydrozoline   
Thiamine   
Thioridazine   
D,L-Thyroxine   
Dextromethorphan Niacinamide Tolbutamine   
Diazepam Nifedipine Triamterene   
Diclofenac Norcodein Trifluoperazine   
Diflunisal Norethindrone Trimethoprim   
Digoxin D-Norpropoxyphene Trimipramine   
Diphenhydramine Noscapine Tryptamine   
Doxylamine D,L-Octopamine D, L-Tyrosine   
Ecgonine hydrochloride Oxalic acid Uric acid   
Ecgonine methylester Oxazepam Verapamil   
(IR,2S)(-)Ephedrine Oxolinic acid Zomepirac Oxazepam   
4-Acetamidophenol Diaoxin D.L-Octopamine   
Acetophenetidin Diphenhydramine Oxalic acid   
N-Acetvprocainamide Doxylamine Oxolinic acid   
Acetvsalicvlic acid Ecaonine dydrochloride Pentobarbital   
Aminopvrine Ecqonine methylester Perphenazine   
Amityptvline (-)--Ephedrine Phencyclidine   
Amorbarbital Fenoprofen Phenelzine   
Amoxicillin Furosemide Phenobarbital   
Ampicillin Gentisic acid Phentermine   
1-Ascorbic Acid Hemoglobin L-Phenylephrine   
D.L-Amphetamine Hydrocortisone -Phenylethylamine   
Apormorphine O-Hydroxyhippuric acid Phenylpropanotamin e   
Aspartame p-Hydroxy- methamphetamine Prednisone   
Atropine 3-Hydroxytyramine D.L-Propanolol   
Benzillic acid Ibuprofen D-Propoxyphene   
Benzoic acid Imipramine D-Pseudoephedrine   
Benzoylecaonine Iproniazid Quinine   
Benzphetamine EPY $( \pm )$ Isoproterenol Ranitidine   
Bilirubin Isoxsuprine Salicylic acid   
$( \pm )$ Chlorpheniramine Ketamine Secobarbital   
Caffeine Ketoprofen Serotonin (5-Hydroxytyramine)   
Cannabidiol Labetalol Sertraline   
Chloralhvdrate Loperamide Sulfamethazine   
Chloramphenicol Maprotiline Sulindac   
Chlordiazepoxide Meperidine Tetrahydrocortisone, 3 Acetate   
Chlorothiazide Meprobamate Tetrahydrocortisone, $\beta$ D glucuronide)   
$( \pm )$ Chlorpheniramine Methadone Tetrahydrozoline   
Chlorpromazine Methoxyphenamine Thiamine   
Chlorquine 0) 3,4-Methylenedioxy- Thioridazine amphetamine   
Cholesterol EY $( + ) 3 , 4$ Methylenedioxy- D.L-Tyrosine

methamphetamine Clomipramine Nalidixic acid Clonidine Nalorphine Cocaine hydrochloride Naloxone Cortisone Naltrexone (-)cotinine Naproxen Creatinine Niacinamide Dextromethlorphan Nifedipine Diazepam Norethindrone Diclolrfenac D-Norpropoxyphene Diflunisal Noscapine

Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Triyptamine   
D.L-Tryptophan   
Tyramine   
Uric acid   
Verapamil   
Zomepirac

f. Specificity

To test the specificity, drug metabolites and other components that are likely to be present in urine samples were tested. Compounds that produced positive results are listed below.

<table><tr><td rowspan=1 colspan=1>AMP(Amphetamine)(d-Amphetamine, Cutoff=1000 ng/mL)</td><td rowspan=1 colspan=1>ResultPositive at 1,000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>1-Amphetamine</td><td rowspan=1 colspan=1>Positive at 50,000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>dl-Amphetamine</td><td rowspan=1 colspan=1>Positive at 3,000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>(+/-) 3,4-methylenedioxyamphetamine(MDA)</td><td rowspan=1 colspan=1>Positive at 5,000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Phentermine</td><td rowspan=1 colspan=1>Positive at 3,000 ng/ml</td></tr><tr><td rowspan=1 colspan=1>d-methamphetamine</td><td rowspan=1 colspan=1>Positive at &gt;100,000</td></tr><tr><td rowspan=1 colspan=1>1-methamphetamine</td><td rowspan=1 colspan=1>Positive at &gt;100,000</td></tr><tr><td rowspan=1 colspan=1>3,4-Methylenedioxyethylamphetamine(MDE)</td><td rowspan=1 colspan=1>Positive at 100,000</td></tr><tr><td rowspan=1 colspan=1>(+/-)3,4-methylenedioxumethamphetamine(MDMA)</td><td rowspan=1 colspan=1>Positive at 100,000</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Secobarbital(Secobarbital, Cutoff=300 ng/mL)</td><td colspan="1" rowspan="1">ResultPositive at 300 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">Positive at 300 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Alphenol</td><td colspan="1" rowspan="1">Positive at 150 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Aprobarbital</td><td colspan="1" rowspan="1">Positive at 200 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Butabarbital</td><td colspan="1" rowspan="1">Positive at 75 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Butathal</td><td colspan="1" rowspan="1">Positive at 100 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Butalbital</td><td colspan="1" rowspan="1">Positive at 2,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Cyclopentobarbital</td><td colspan="1" rowspan="1">Positive at 600 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Pentobarbital</td><td colspan="1" rowspan="1">Positive at 300 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">Positive at 100 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Oxzaepam(Oxazepam, Cutoff=300 ng/mL)</td><td colspan="1" rowspan="1">ResultPositive at 300 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Alprazolam</td><td colspan="1" rowspan="1">Positive at 200 ng/mL</td></tr><tr><td colspan="1" rowspan="1">a-Hydroxyalprazolam</td><td colspan="1" rowspan="1">Positive at 1,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Bromazepam</td><td colspan="1" rowspan="1">Positive at 1,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">Positive at 1,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Clonazepam HCI</td><td colspan="1" rowspan="1">Positive at 800 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Clobazam</td><td colspan="1" rowspan="1">Positive at 100 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Clonazepam</td><td colspan="1" rowspan="1">Positive at 800 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Clorazepate dipotassium</td><td colspan="1" rowspan="1">Positive at 200 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Delorazepam</td><td colspan="1" rowspan="1">Positive at 1,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Desalkylflurazepam</td><td colspan="1" rowspan="1">Positive at 400 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Positive at 200 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Estazolam</td><td colspan="1" rowspan="1">Positive at 2,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Flunitrazepam</td><td colspan="1" rowspan="1">Positive at 400 ng/mL</td></tr><tr><td colspan="1" rowspan="1">D,L-Lorazepam</td><td colspan="1" rowspan="1">Positive at 1,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Midazolam</td><td colspan="1" rowspan="1">Positive at 12,500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Nitrazepam</td><td colspan="1" rowspan="1">Positive at 100 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Norchlordiazepoxide</td><td colspan="1" rowspan="1">Positive at 200 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Nordiazepam</td><td colspan="1" rowspan="1">Positive at 400 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Temazepam</td><td colspan="1" rowspan="1">Positive at 100 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Trazolam</td><td colspan="1" rowspan="1">Positive at 2,500 ng/mL</td></tr></table>

# 2 Comparison Studies

The method comparison for the Wondfo Amphetamine Urine Test, Wondfo Secobarbital Urine Test and Wondfo Oxazepam Urine Test was performed in-house with three laboratory assistants with relevant experience and a lay person with no experience other than reading the instructions for use. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were blind labeled and compared to GC/MS results. The results are presented in the table below:

Amphetamine   

<table><tr><td colspan="1" rowspan="1">Cupformat</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">LowNegative byGC/MS(less than-50%)</td><td colspan="1" rowspan="1">Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td colspan="1" rowspan="1">Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td colspan="1" rowspan="1">High Positiveby GC/MS(greater than+50%</td></tr><tr><td colspan="1" rowspan="2">ViewerA</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">ViewerB</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">ViewerC</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">LayPerson</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">11     •</td><td colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr></table>

# Amphetamine

<table><tr><td rowspan=1 colspan=1>DipCardformat</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than÷50%)</td></tr><tr><td rowspan=2 colspan=1>ViewerA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerB</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerC</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample number</td><td rowspan=1 colspan=1>GC/MS result</td><td rowspan=1 colspan=1>Cup formatViewer result</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP63</td><td rowspan=1 colspan=1>987</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP65</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP62</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP65</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>AMP62</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay person</td><td rowspan=1 colspan=1>AMP62</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay person</td><td rowspan=1 colspan=1>AMP63</td><td rowspan=1 colspan=1>987</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>AMP65</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample number</td><td rowspan=1 colspan=1>GC/MS result</td><td rowspan=1 colspan=1>Dip Cardformat viewerresults</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP62</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP62</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP65</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>AMP35</td><td rowspan=1 colspan=1>797</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>AMP63</td><td rowspan=1 colspan=1>987</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>AMP35</td><td rowspan=1 colspan=1>797</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay person</td><td rowspan=1 colspan=1>AMP65</td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>positive</td></tr></table>

# Secobarbital

<table><tr><td rowspan=1 colspan=1>Cupformat</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>ViewerA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerB</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerC</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Secobarbital   

<table><tr><td rowspan=1 colspan=1>DipCardformat</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>ViewerA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerB</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerC</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant result   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">Cup formatViewer result</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BAR61</td><td colspan="1" rowspan="1">293</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BAR216</td><td colspan="1" rowspan="1">280</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BAR34</td><td colspan="1" rowspan="1">243</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BAR216</td><td colspan="1" rowspan="1">280</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BAR35</td><td colspan="1" rowspan="1">237</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BAR61</td><td colspan="1" rowspan="1">293</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BAR216</td><td colspan="1" rowspan="1">280</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">Dip Cardformat viewerresults</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BAR34</td><td colspan="1" rowspan="1">243</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">,BAR216</td><td colspan="1" rowspan="1">280</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BAR34</td><td colspan="1" rowspan="1">243</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BAR61</td><td colspan="1" rowspan="1">293</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BAR35</td><td colspan="1" rowspan="1">237</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BAR216</td><td colspan="1" rowspan="1">280</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BAR34</td><td colspan="1" rowspan="1">243</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BAR35</td><td colspan="1" rowspan="1">237</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BAR61</td><td colspan="1" rowspan="1">293</td><td colspan="1" rowspan="1">positive</td></tr></table>

Oxazepam   

<table><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between -50%and cutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Oxazepam   

<table><tr><td rowspan=1 colspan=1>DipCardformat</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>ViewerA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerB</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>ViewerC</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant result   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample number</td><td rowspan=1 colspan=1>GC/MS result</td><td rowspan=1 colspan=1>Cup formatViewer result</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>BZO32</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO32</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO211</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZO34</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZ065</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZO34</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZ065</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZO211</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample number</td><td rowspan=1 colspan=1>GC/MS result</td><td rowspan=1 colspan=1>Dip Cardformat viewerresults</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>BZO34</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>BZ065</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO32</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO211</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZO34</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZO65</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZO32</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZ034</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>positive.</td></tr><tr><td rowspan=1 colspan=1>Lay Person</td><td rowspan=1 colspan=1>BZO211</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>positive</td></tr></table>

Test Cup format:

A lay user study was performed at three intended user sites with 140 lay persons. Participants in the study were 58 females and 82 males tested the amphetamine samples, 59 females and 81 males tested the secobarbital samples 71 females and 69 males tested the oxazepam samples. They had diverse educational and professional backgrounds and ranged in age from 21 to ${ > } 5 0$ . Urine samples were prepared at the following concentrations; negative, $+ / - 7 5 \%$ $+ / - 5 0 \%$ $+ 1 - 2 5 \%$ of the cutoff by spiking drug(s) into drug free-pooled urine specimens. The concentrations of the samples were confirmed by GC/MS. Each sample was aliquoted into individual containers and blind-labeled. Each participant was provided with the package insert, 1 blind labeled samples and a device. The results are summarized below.

<table><tr><td rowspan=1 colspan=2>Cup format</td><td rowspan=2 colspan=1>Number ofsamples</td><td rowspan=1 colspan=2>OTC user</td><td rowspan=2 colspan=1>%AgreementWithGC/MS</td></tr><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=7 colspan=1>Amphetamine</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>.-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=7 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=7 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr></table>

Dip Card format:

A lay user study was performed at three intended user sites with 140 lay persons. Participants in the study were 61 females and 79 males tested the amphetamine samples, 64 females and 76 males tested the secobarbital samples 66 females and 74 males tested the oxazepam samples. They had diverse educational and professional backgrounds and ranged in age from 21 to ${ > } 5 0$ . Urine samples were prepared at the following concentrations; negative, $+ 1 . 7 5 \%$ $+ 1 . 5 0 \%$ , $+ / - 2 5 \%$ of the cutoff by spiking drug(s) into drug free-pooled urine specimens. The concentrations of the samples were confirmed by GC/MS. Each sample was aliquoted into individual containers and blind-labeled. Each participant was provided with the package insert, 1 blind labeled samples and a device. The results are summarized below.

<table><tr><td rowspan=1 colspan=2>Dip card format</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>OTC user</td><td rowspan=2 colspan=1>%AgreementWithGC/MS</td></tr><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Number ofsamples</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=7 colspan=1>Amphetamine</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=7 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=7 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr></table>

3Clinical Studies Not applicable

12. Conclusion

Based on the test principle and performance characteristics of the device, it's concluded that Wondfo Amphetamine, Secobarbital, and Oxazepam Urine Tests are substantially equivalent to the predicate.

Guangzhou Wondfo Biotech Co., Ltd. c/o Joe Shia   
LSI International Inc.   
504 East Diamond Ave., Suite F   
Gaithersburg, MD 20877

Re: k121987 Trade Name: Wondfo Amphetamine Urine Test Wondfo Secobarbital Urine Test Wondfo Oxazepam Urine Test Regulation Number: 21 CFR §862.3100 Regulation Name: Amphetamine test system Regulatory Class: Class II Product Codes: DKZ, DIS, JXM Dated: June 18, 2012 Received: July 6, 2012

Dear Mr. Shia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling. and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/dbb6ee30631038e65bacf733cb457eb512884ce03b912cf8d2a3ca156abbfd2b.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Device Name: Wondfo Amphetamine Urine Test

Indications for Use:

Wondfo Amphetamine Urine Test is an immunochromatographic assay for the qualitative determination of / cup format. It is intended for prescription use and over the counter use.

T  e at us obtain a conformed analytical result. GMs is the preferred confirmatory method. Clinical consideration and u u is positive.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K121987

Page 1 of_3

Indications for Use:

WoarbUaphselatt lu card format and a cup format. It is intended for prescription use and over the counter use.

T  e avles obtan a conformed analytical result. G/Ms is the preferred confirmatory method Clinical consideration and a u is positive.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/ecdf478446799df29561b4b7ddcc27c6bf799cad7fba74e97a5023aa22d119e3.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 5101m) K121987

510(k) Number (if known):_K121987

Device Name: Wondfo Oxazepam Urine Test

Indications for Use:

Wono Oxazepam UrineTest s n mmuochromatographicassay o hequalitative determinationOxazepm eolizeiti vl dip card format and a cup format. It is intended for prescription use and over the counter use.

T  etu obtain a conformed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and u is positive.

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/e0584b700eadb0b61da208260c1eedc0ce552b2041d43ff38e2a60b77364fc32.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

5101) 1212/987